Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium

BACKGROUND: We assessed the real world costs and cost-effectiveness of the addition of trastuzumab in HER2 positive early breast cancer compared to chemotherapy alone in the Dutch daily practice as opposed to the results based on trial data and based on a subset of patients that were treated accordi...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Seferina, Shanly C., Ramaekers, Bram L.T., de Boer, Maaike, Dercksen, M. Wouter, van den Berkmortel, Franchette, van Kampen, Roel J.W., van de Wouw, Agnès J., Voogd, Adri C., Tjan Heijnen, Vivianne C.G., Joore, Manuela A.
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2017
נושאים:
Clinical Research Paper
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5668034/
https://ncbi.nlm.nih.gov/pubmed/29108301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.16985
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים